ISEE News and Press, IVERIC bio Inc. From 02/28/23

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, 2023, at 2:50 p.m. Eastern Time. Investors a...

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Tim...

IVERIC bio ( NASDAQ: ISEE ) on Thursday said the U.S. Food and Drug Administration has completed its filing review and accepted the company’s new drug application for Avacincaptad Pegol. Shares +7.5% at $21.50 after hours. The NDA has been granted priority review wi...

- PDUFA goal date is August 19, 2023 - IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigationa...

Summary Small caps outperformed the Nasdaq Composite last year as stocks fell due to the Federal Reserve's efforts to control inflation. Market fears are mounting that the economy may slip into a recession, but there are opportunities in small-cap stocks. The potential risk of a lon...

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the Company’s business strategy and in overseeing the development ...

IVERIC bio Gene Therapy LLC, a unit of clinical-stage biotech IVERIC bio ( NASDAQ: ISEE ), has sold the ownership rights for preclinical gene therapy candidates IC-100 and IC-200 to privately held Opus Genetics Inc. for cash and stock on Dec. 23. Per the terms, Opus will pay $500K upf...

- Commercial launch preparations continue to accelerate - IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP),...

Summary Recent developments on Zimura label improve investor attractiveness. Market for underlying treatments continues to grow with ageing population. Here we've done a deep dive into the market opportunity and covered each of the respective treatment segments. Rate buy, price ...

IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition, in connection wi...